Rapid Information on OLM No 220 140608.doc

Rapid Information on Olmesartan and other ARBs No.220 2014/06/08 　　　　　　　　　　　　　　　　　 　　　　　　　　　Be the first to know! 　　　 　 　　 (Toru Komai, Ph.D.) 220-1: The combination of olmesartan with azelnidipine is more beneficial with regard to BP control and metabolic outcome than the combination of olmesartan with low dose trichlormethiazide in hypertensive patients with diabetes mellitus. Title：Comparison of effects of azelnidipine and trichlormethiazide in combination with olmesartan on blood pressure and metabolic parameters in hypertensive type 2 diabetic patients. 2 220-2: A small but significantly increased diabetes incidence was found in olmesartan initiators as compared to losartan initiators in a large nationwide population-based cohort in Taiwan. Title：Different angiotensin receptor blockers and incidence of diabetes: a nationwide population-based cohort study. 3-4 220-3: A case report: Olmesartan-induced enteropathy resembling celiac disease. Title：Olmesartan-induced enteropathy resembling celiac disease. 4 220-4: Overall, 54 patients, equally distributed between men and women, have developed a sprue-like enteropathy associated with olmesartan treatment for arterial hypertension: A systematic review. Title：Systematic review: sprue-like enteropathy associated with olmesartan. 5 Abbreviations: BP: blood pressure, SBP/DBP: systolic/ diastolic BP, RAS: renin–angiotensin system, Ang II: angiotensin II, ARB: angiotensin II receptor blocker, CCB: calcium channel blocker, ACE-inhibiyor: angiotensin converting enzyme inhibitor, HR: hazard ratio, OR: odds ratio, 220-1: The combination of olmesartan with azelnidipine is more beneficial with regard to BP control and metabolic outcome than the combination of olmesartan with low dose trichlormethiazide in hypertensive patients with diabetes mellitus. The recent ACCO